Ropinirole

Evidence Level: L3

Predicted Indications: 10

Ropinirole
Ropinirole: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder

## Pharmacist Assessment Report

Ropinirole: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder

One-Sentence Summary

Ropinirole is a dopamine agonist originally used to treat restless legs syndrome and Parkinson disease. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), with no registered clinical trials but 8 publications in the compiled data, including one case report in a child and one 2026 study of ropinirole added to methylphenidate that is still awaiting verification.

Quick Overview

Item	Content
Original Indication	Restless legs syndrome, Parkinson disease (the Singapore licence records contain no approved-indication text)
Predicted New Indication	Attention deficit-hyperactivity disorder
TxGNN Prediction Score	99.99%
Evidence Level	L3
Singapore Market Status	✓ Marketed
Number of Registrations	5
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Ropinirole is known to be a D2/D3 dopamine receptor agonist, and it has established use in restless legs syndrome and Parkinson disease.

ADHD involves dysregulation of dopamine signalling, and it often occurs together with restless legs syndrome. Because restless legs syndrome is an approved use of ropinirole, the two conditions may share a dopaminergic pathway. A published review (Cortese et al., 2005) discusses this association and the potential for common treatments.

The direct clinical support is thin. One case report describes a 6-year-old boy with ADHD and restless legs/periodic limb movements, in whom ropinirole improved both ADHD symptoms and sleep. A 2026 publication (PMID 42640474) appears to be a randomized, double-blind, placebo-controlled trial of ropinirole added to methylphenidate in 66 children and adolescents aged 6–17. Its results are not available in the compiled data. If its design is confirmed, the evidence level could be raised after full-text review.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
42640474	2026	RCT (suspected from title; needs verification)	Eur Child Adolesc Psychiatry	8-week, double-blind study in 66 outpatients aged 6–17 comparing ropinirole plus methylphenidate with placebo plus methylphenidate; results not available in the data
16218085	2005	Review	Sleep	Reviews the association between restless legs syndrome and ADHD and the possibility of shared treatments
18656214	2008	Review	Rev Neurol	General review of restless legs syndrome (a sensorimotor disorder affecting 2–3% of people in Western countries)
15866437	2005	Case report	Pediatr Neurol	A 6-year-old with ADHD and restless legs had a significant improvement in ADHD symptoms and sleep with ropinirole
34182128	2021	Preclinical	Pharmacol Res	Receptor heteromerization between α2A adrenoceptors and dopamine D4 variants, relevant to ADHD and impulse control
30950895	2019	Safety report	Cornea	Corneal edema in 3 patients exposed to dopaminergic agents

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN13763P	Requip PD 24 Hour Prolonged Release Tablets (2mg)	Film-coated extended-release tablet	Not stated in the available records
SIN13764P	Requip PD 24 Hour Prolonged Release Tablets (4mg)	Film-coated extended-release tablet	Not stated in the available records
SIN10975P	REQUIP TABLET 2 mg	Film-coated tablet	Not stated in the available records
SIN10976P	REQUIP TABLET 0.25 mg	Film-coated tablet	Not stated in the available records
SIN11018P	REQUIP TABLET 1 mg	Film-coated tablet	Not stated in the available records

Safety Considerations

Disease-level cautions (from a knowledge graph, not label text): Ropinirole is flagged as contraindicated or to be used with caution in multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension and other hypotensive disorders, drug-induced dyskinesia, liver failure, and psychotic disorders (including schizophreniform and schizoaffective disorders and mental disorders in general).
Drug Interactions: 100 interactions were found. The ones rated Moderate are morphine (including liposomal morphine), cimetidine, dronabinol, obeticholic acid, metoclopramide, nabilone and opium. Several others are rated Unknown, including calcitriol, phentermine, pantoprazole and glimepiride.
Other signals in the literature: A Swedish register study found an increased risk of gambling disorder with ropinirole, pramipexole, and aripiprazole. Corneal edema has been reported with dopaminergic agents. These are relevant for a paediatric population.

Please refer to the package insert for the full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high, and there is a plausible dopaminergic link through restless legs syndrome. However, there are no registered trials, and the only direct evidence is a single case report plus one 2026 study whose design and results have not been verified. Package insert safety data are also missing, and the population would be children.

To proceed, the following is needed:

Full-text review of PMID 42640474 to confirm its design, results, and safety findings; if it is a sound RCT, the evidence level and decision can be reconsidered
Package insert warnings and contraindications from the HSA, and the approved indication text for the Singapore licences
Detailed mechanism of action data
Paediatric safety review, including impulse control, psychiatric effects, and low blood pressure
Confirmation of any registered or ongoing ADHD trials
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.